Scienture Holdings Inc. Common Stock (SCNX)

About SCNX

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients w…

Sector

Health Care

Industry

Other Pharmaceuticals

Employees

4

Website

www.trxadehealth.com/

Fundamentals

1-day range

$0.381$0.3999

Market cap

$15.72M

P/E (trailing)

—

P/E (forward)

Infinity

EPS (trailing)

$-0.75

Dividend yield

—

Beta

3.08

Avg. volume

2.55M

Ex-dividend date

July 19, 2024

Dividend pay date

July 24, 2024

Forecasts

1 analyst ratings

Scienture Holdings Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• SCNX

  Scienture Holdings Inc. Common Stock

  $0.3938

  ▲ 3.63%
  Market cap $15.72MP/E —
  $0.2382$2.6
• COSM

  Cosmos Health Inc. Common Stock

  $0.225

  ▲ 4.17%
  Market cap $14.59MP/E —
  $0.1616$1.32
• HKPD

  Cellyan Biotechnology Co. Ltd Class A Ordinary Shares

  $0.36

  ▼ 11.33%
  Market cap $16.93MP/E —
  $0.31$1.82
• NUS

  Nu Skin Enterprises Inc. Common Stock

  $4.85

  ▲ 2.54%
  Market cap $250.52MP/E 4.30
  $4.49$14.62
• HLF

  Herbalife Ltd. Common Shares

  $12.43

  ▲ 0.65%
  Market cap $1.32BP/E 7.68
  $7.56$20.4
• COR

  Cencora Inc. Common Stock

  $322.02

  ▲ 0.25%
  Market cap $60.00BP/E 22.54
  $244.82$377.54
• MCK

  McKesson Corporation Common Stock

  $894.35

  ▲ 0.43%
  Market cap $99.43BP/E 21.89
  $677.28$999

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Scienture Holdings Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $343.639K Miss $1.964M Estimate
  benzinga · 8/14/2026
• SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
  Yahoo · 8/14/2026
• Scienture Holdings Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $343.639K Miss $1.964M Estimate
  Benzinga · 8/14/2026
• SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product
  Yahoo · 8/12/2026
• SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
  Yahoo · 8/12/2026
• EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US
  Yahoo · 8/12/2026

Institutional Ownership

March 31, 2026

Total shares held

1.22M

Total value held

$324.7K

Institutional holders

13